BTIG Reiterates Buy on Maze Therapeutics, Maintains $46 Price Target

BTIG analyst Julian Harrison has reiterated a Buy rating on Maze Therapeutics (NASDAQ: MAZE) and has maintained a price target of $46 for the stock. This affirmation suggests confidence in the company's future performance.